Skip to main content

Advertisement

SpringerLink
Log in

Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Swain SM, Tang G, Lucas PC, Robidoux A, Goerlitz D, Harris BT et al (2019) Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05398-3

    Article  PubMed  PubMed Central  Google Scholar 

  2. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN et al (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14:1183–1192

    Article  CAS  Google Scholar 

  3. Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L et al (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393:2599–2612

    Article  CAS  Google Scholar 

Download references

Funding

There is no funding involved with this publication.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Max Superspecialty Hospital, W-3, Sector 1, Vaishali, Ghaziabad, UP, 201012, India

    Arun Kumar Goel & Vaishali Zamre

  2. Department of Radiation Oncology, Max Superspecialty Hospital, Vaishali, Ghaziabad, India

    Shreebha Hari

Authors
  1. Arun Kumar Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vaishali Zamre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shreebha Hari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arun Kumar Goel.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goel, A.K., Zamre, V. & Hari, S. Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial. Breast Cancer Res Treat 183, 489–490 (2020). https://doi.org/10.1007/s10549-020-05790-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-05790-4

Search

Navigation